Aukrust P, Müller F, Ueland T, Berget T, Aaser E, Brunsvig A, Solum N O, Forfang K, Frøland S S, Gullestad L
Section of Clinical Immunology and Infectious Diseases, Research Institute for Internal Medicine, Department of Cardiology, University of Oslo, Norway.
Circulation. 1999 Aug 10;100(6):614-20. doi: 10.1161/01.cir.100.6.614.
The CD40 ligand (CD40L) on activated T cells and platelets may be activating matrix metalloproteinases, inducing procoagulant activity, and be involved in the pathogenesis of acute coronary syndromes by promoting plaque rupture in atheroma.
To study the role of CD40L-CD40 interaction in coronary disease, we analyzed levels of soluble (s) and membrane-bound CD40L in the peripheral blood from 29 patients with stable angina, 26 with unstable angina, and 19 controls. Our main findings follow. (1) Patients with unstable angina had significantly raised serum levels of sCD40L when compared with patients with stable angina and controls. (2) Platelets could release large amounts of sCD40L when stimulated ex vivo with the thrombin receptor-agonist peptide SFLLRN in both patients and controls. (3) Platelets in patients with unstable angina were characterized ex vivo by decreased intracellular levels and decreased SFLLRN-stimulated release of sCD40L, which may possibly represent a higher percentage of degranulated platelets in these patients. (4) T cells in patients with unstable angina had enhanced surface expression of CD40L and increased release of sCD40L on anti-CD3/anti-CD28 stimulation in vitro when compared with patients with stable angina and controls. (5) Recombinant CD40L and serum from patients with unstable angina who had high sCD40L levels induced enhanced release of monocyte chemoattractant peptide-1 from mononuclear cells, a CC-chemokine involved in the pathogenesis of atherosclerosis.
This first demonstration of enhanced levels of soluble and membrane-bound forms of CD40L in angina patients, with particularly high levels in patients with unstable angina, suggests that CD40L-CD40 interaction may play a pathogenic role in both the long-term atherosclerotic process and in the triggering and propagation of acute coronary syndromes.
活化的T细胞和血小板上的CD40配体(CD40L)可能激活基质金属蛋白酶,诱导促凝活性,并通过促进动脉粥样硬化斑块破裂参与急性冠状动脉综合征的发病机制。
为研究CD40L-CD40相互作用在冠心病中的作用,我们分析了29例稳定型心绞痛患者、26例不稳定型心绞痛患者和19例对照者外周血中可溶性(s)和膜结合型CD40L的水平。我们的主要发现如下。(1)与稳定型心绞痛患者和对照者相比,不稳定型心绞痛患者血清sCD40L水平显著升高。(2)在患者和对照者中,用凝血酶受体激动肽SFLLRN体外刺激血小板时,血小板可释放大量sCD40L。(3)不稳定型心绞痛患者的血小板在体外表现为细胞内水平降低,SFLLRN刺激后sCD40L释放减少,这可能代表这些患者中脱颗粒血小板的比例较高。(4)与稳定型心绞痛患者和对照者相比,不稳定型心绞痛患者的T细胞在体外经抗CD3/抗CD28刺激后,CD40L的表面表达增强,sCD40L的释放增加。(5)来自sCD40L水平高的不稳定型心绞痛患者的重组CD40L和血清诱导单核细胞趋化蛋白-1从单核细胞中释放增加,单核细胞趋化蛋白-1是一种参与动脉粥样硬化发病机制的CC趋化因子。
首次证明心绞痛患者中可溶性和膜结合型CD40L水平升高,尤其是不稳定型心绞痛患者水平特别高,提示CD40L-CD40相互作用可能在长期动脉粥样硬化过程以及急性冠状动脉综合征的触发和进展中起致病作用。